Dianthus Therapeutics reported interim Part A results for 40 CIDP patients, showing a 75% confirmed responder rate with a clean safety profile. Part B data through 52 weeks in responders is expected by end-2026, serving as a key durability and commercial-readout. Analysts suggest riliprubart underperforms Claseprubart and CAPTIVATE success could broaden DNTH's CIDP opportunities.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder that presents significant challenges and creates demand for therapeutic solutions. For DNTH, increased focus on CIDP could point to investment opportunities in emerging treatments addressing the gaps in patient care.
